Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Characteristics and outcomes of CEBPA bZIP in-frame mutations in de novo and treated secondary acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAlexandre BazinetGIGhayas C. IssaTKTapan M. Kadia

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows venetoclax with induction therapy improves complete remission rates in AML patients.

Key Points

  • This research aims to evaluate the impact of CEBPA bZIP in-frame mutations on treatment outcomes in acute myeloid leukemia.
  • Conducted a retrospective study on adult patients with CEBPA bZIP-Inf mutations in AML.
  • Analyzed outcomes based on the type of induction therapy: frontline intensive or low intensity.
  • Assessed complete remission rates and other relevant clinical outcomes.
  • Patients receiving intensive chemotherapy showed an 88% complete remission rate.
  • Venetoclax added to therapy led to high rates of measurable residual disease negativity.
  • Overall survival and relapse-free survival were favorable in the de novo cohort but lower in the low-intensity cohort.

Cite This Study

Bazinet et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d68bhttps://doi.org/10.1182/blood-2025-5167
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Enhanced prognosis of acute myeloid leukaemia patients with dm CEBPA bZIP ‐inf mutations: Insights from a multicentre Chinese cohort study2026
  2. 2Bzip in-frame mutations might abrogate the adverse prognosis of therapy-related CEBPA-mutated AML2025
  3. 3CCAAT/enhancer‐binding protein alpha basic leucine zipper in‐frame insertion/deletion ( <scp> <i>CEBPA</i> bZIP </scp> ‐ <scp>InDel</scp> ‐inf) defines a favourable‐prognosis subgroup in <scp> <i>CEBPA</i> </scp> ‐mutated acute myeloid leukaemia2026
  4. 4Refinement of the prognostic impact of somatic <i>CEBPA</i> bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)2024 · 5 citations
  5. 5Clinical and Prognostic Significance of CEBPA Mutations in Myelodysplastic Syndromes2026